MedPath
TGA Approval

ODEFSEY emtricitabine (200 mg), rilpivirine (25 mg), tenofovir alafenamide (25 mg) fixed-dose combination tablet (260634)

260634

ODEFSEY emtricitabine (200 mg), rilpivirine (25 mg), tenofovir alafenamide (25 mg) fixed-dose combination tablet

Gilead Sciences Pty Ltd

August 30, 2016

Medicine

Medicine

Active

Registered

Product Information

Consumer Medicine Information

https://medical-cdn.nocode.com/drug_tga/1f324d3b07c3376375279ebfb98446b3.pdf

Product Information

https://medical-cdn.nocode.com/drug_tga/4d3dda2a3a179e3d7022b679b92622df.pdf

Active Ingredients

emtricitabine

rilpivirine hydrochloride

tenofovir alafenamide fumarate

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

ODEFSEY emtricitabine (200 mg), rilpivirine (25 mg), tenofovir alafenamide (25 mg) fixed-dose combination tablet (260634) - TGA 批准文号 | MedPath